

# Resource Summary Report

Generated by [Kravitz](#) on Sep 10, 2026

## Biomarkers Consortium

RRID:SCR\_003121

Type: Tool

### Proper Citation

Biomarkers Consortium (RRID:SCR\_003121)

### Resource Information

**URL:** <http://www.biomarkersconsortium.org/>

**Proper Citation:** Biomarkers Consortium (RRID:SCR\_003121)

**Description:** Consortium serving to develop and qualify promising biomarkers in order to help accelerate the delivery of successful new technologies, medicines and therapies for prevention, early detection, diagnosis and treatment of disease. Current core disease areas of focus include Cancer, Inflammation and Immunity, Metabolic Disorders, and Neuroscience. One of the most difficult tasks facing biomarker assessment and evaluation is harmonizing the approaches of various stakeholders--government, industry, non-profits and foundations, providers, and academic institutions. Consortium founding members and other partners recognize the critical need for a coordinated cross-sector partnership effort. The Biomarkers Consortium brings together the expertise and resources of various partners to rapidly identify, develop, and qualify potential high-impact biomarkers. Biomarkers Consortium Goals: \* Facilitate the development and qualification of biomarkers using new and existing technologies; \* Help qualify biomarkers for specific applications in diagnosing disease, predicting therapeutic response or improving clinical practice; \* Generate information useful to inform regulatory decision making; \* Make consortium project results broadly available to the entire scientific community.

**Abbreviations:** BC

**Synonyms:** The Biomarkers Consortium, FNIH Biomarkers Consortium

**Resource Type:** consortium, data or information resource, funding resource, organization portal, portal

**Keywords:** human, biomarker, clinical, translational research, drug development, preventive medicine, medical diagnostics, consortium, biomarker development, neuroscience

**Funding:** NIH Blueprint for Neuroscience Research

**Availability:** Free, Freely available

**Resource Name:** Biomarkers Consortium

**Resource ID:** SCR\_003121

**Alternate IDs:** nif-0000-00559

**Record Creation Time:** 20220129T080217+0000

**Record Last Update:** 20260905T132458+0000

---

## Ratings and Alerts

No rating or validation information has been found for Biomarkers Consortium.

No alerts have been found for Biomarkers Consortium.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 9 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [Kravitz](#) .

Rafea M, et al. (2019) Applying Machine Learning of Erythrocytes Dynamic Antigens Store in Medicine. Frontiers in molecular biosciences, 6, 19.

Yildirim O, et al. (2016) Opportunities and Challenges for Drug Development: Public-Private Partnerships, Adaptive Designs and Big Data. Frontiers in pharmacology, 7, 461.

Shankar SS, et al. (2016) Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of  $\beta$ -Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series. Diabetes care, 39(9), 1602.

Skrypek N, et al. (2015) The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2. Oncotarget, 6(13), 10853.

Harris JR, et al. (2012) Toward a roadmap in global biobanking for health. European journal of human genetics : EJHG, 20(11), 1105.

Agúndez JA, et al. (2012) Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacology. Frontiers in pharmacology, 3, 2.

Mishra A, et al. (2010) Cancer biomarkers: are we ready for the prime time? *Cancers*, 2(1), 190.

, et al. (2010) White paper on imaging biomarkers. *Insights into imaging*, 1(2), 42.

Weigelt J, et al. (2009) The case for open-access chemical biology. A strategy for pre-competitive medicinal chemistry to promote drug discovery. *EMBO reports*, 10(9), 941.